Read news on recommended phase with our app.
Read more in the app
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Phase 1 Study Supports Recommended Phase 3 Dose for Investigational EGFR x HER3 Antibody-Drug Conjugate in EGFR-Mutated Lung Cancer
